IOL Chemicals And PharmaceuticalsNSE:IOLCP +6.49%63 Return-on-Tangible-Equity is 11.92% as of Mar. 2026, which is 7% above its 10-year median of 11.15. GuruFocus rates NSE:IOLCP with a GF Score™ of 63/100 and a GF Value™ of ₹93.67 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 896 Drug Manufacturers companies, IOL Chemicals And Pharmaceuticals ranks better than 50.33% on this metric.
The historical rank and industry rank for IOL Chemicals And Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
NSE:IOLCP'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 2.52 Med: 11.15 Max: 68.77
Current: 7.95
During the past 13 years, IOL Chemicals And Pharmaceuticals's highest Return-on-Tangible-Equity was 68.77%. The lowest was 2.52%. And the median was 11.15%.
NSE:IOLCP's Return-on-Tangible-Equity is ranked better than 50.33% of 896
companies
in the Drug Manufacturers industry
Industry Median: 7.795
vs NSE:IOLCP: 7.95
IOL Chemicals And Pharmaceuticals (NSE:IOLCP) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
IOL Chemicals And Pharmaceuticals Return-on-Tangible-Equity Related Terms
IOL Chemicals And Pharmaceuticals Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IOL Chemicals And Pharmaceuticals Return-on-Tangible-Equity Chart
NSE:IOLCP vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, IOL Chemicals And Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IOL Chemicals And Pharmaceuticals Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, IOL Chemicals And Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where IOL Chemicals And Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.92% mean?
IOL Chemicals And Pharmaceuticals (NSE:IOLCP) has a Return-on-Tangible-Equity of 11.92% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on IOL Chemicals And Pharmaceuticals and its competitors. This is near median its historical median of 11.15. Over the past decade, IOL Chemicals And Pharmaceuticals' Return-on-Tangible-Equity has ranged from 2.52 to 68.77. According to the industry distribution chart, IOL Chemicals And Pharmaceuticals ranks #445 out of 896 companies in the Drug Manufacturers industry, placing it in the top 49.7%.
Is IOL Chemicals And Pharmaceuticals' Return-on-Tangible-Equity too high?
IOL Chemicals And Pharmaceuticals' current Return-on-Tangible-Equity of 11.92% is near median its 10-year median of 11.15. Over the past 10 years, this metric has ranged from a low of 2.52 to a high of 68.77. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.80. IOL Chemicals And Pharmaceuticals' value of 11.92% is 52.9% above this industry median. Based on the distribution chart, IOL Chemicals And Pharmaceuticals ranks #445 out of 896 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, IOL Chemicals And Pharmaceuticals has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IOL Chemicals And Pharmaceuticals' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, IOL Chemicals And Pharmaceuticals ranks #445 out of 896 companies for Return-on-Tangible-Equity. This puts IOL Chemicals And Pharmaceuticals in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.80. IOL Chemicals And Pharmaceuticals' value of 11.92% is 52.9% above this benchmark. Historically, IOL Chemicals And Pharmaceuticals' own Return-on-Tangible-Equity has ranged from 2.52 to 68.77 over the past decade. While the company's 10-year median is 11.15 vs. the industry median of 7.80, IOL Chemicals And Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.80, based on 896 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IOL Chemicals And Pharmaceuticals's current Return-on-Tangible-Equity of 11.92% is 52.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on IOL Chemicals And Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IOL Chemicals And Pharmaceuticals's current Return-on-Tangible-Equity is 11.92%, which is near median its own 10-year median of 11.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IOL Chemicals And Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, IOL Chemicals And Pharmaceuticals (NSE:IOLCP) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹93.67, compared to a current price of ₹142.33 — trading 51.9% above its estimated fair value. The current Return-on-Tangible-Equity is 11.92%, which is near median its 10-year median of 11.15 and 52.9% above the Drug Manufacturers industry median of 7.80. IOL Chemicals And Pharmaceuticals' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For IOL Chemicals And Pharmaceuticals (NSE:IOLCP), the current Return-on-Tangible-Equity is 11.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IOL Chemicals And Pharmaceuticals (NSE:IOLCP) Overvalued in 2026?
Based on GuruFocus' analysis, IOL Chemicals And Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹142.33 is trading 51.9% above its estimated GF Value™ of ₹93.67.
GuruFocus considers IOL Chemicals And Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:IOLCP:
Return-on-Tangible-Equity: 11.92% (near median its 10-year median of 11.15)
GF Value™: ₹93.67 vs. price of ₹142.33 (51.9% above fair value)
Industry Position: 52.9% above the Drug Manufacturers median (#445 of 896)
No single metric tells the full story. See the NSE:IOLCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IOL Chemicals And Pharmaceuticals Business Description
IOL Chemicals And Pharmaceuticals Ltd is an India-based pharmaceutical company. The primary activity of the group is the manufacturing and sale of drugs and organic chemicals. The business activity is functioned through the Chemicals and Pharmaceutical segments. The Chemicals segment produces and sells chemicals such as Ethyl Acetate, Acetic Anhydride, Acetyl Chloride, Mono Chloro Acetic Acid, and Iso Butyl benzene, whereas the Pharmaceutical segment produces and sells various active pharmaceutical ingredients such as Ibuprofen, Metformin, Fenofibrate, Lamotrigine, and others. It derives prime revenue from the Pharmaceutical segment. Geographically, the group's products are sold in both the Indian and international markets.
63GF Score
Get the complete analysis for NSE:IOLCP
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:IOLCP has been successfully added to your 
